Catch up on the top radiology content of the past week.
|Articles|April 25, 2001
Nycomed releases lung agent in Europe
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and
Advertisement
NeoSpect, a product for noninvasive diagnosis of suspected lung cancer, has entered the European market. The nuclear medicine product has been on the U.S. market since 1999 under the trade name NeoTect, which is being comarketed by Nycomed Amersham and Berlex. Developed and marketed by Nycomed Amersham Imaging, the agent binds selectively to the somatostatin receptor, which is overexpressed by malignant tumors in the lung. Current diagnostic methods typically uncover lung cancer only in advanced stages, offering little hope of recovery to the patient. NeoSpect has a high sensitivity for this type of cancer, raising prospects for early detection, according to the company. The high specificity may allow physicians to forego biopsy, otherwise required for a definitive diagnosis.
Advertisement
Related to this article
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
In the first of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss current challenges with reimbursement for AI in radiology.
Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.
The use of adjunctive AI for pulmonary nodule assessment on chest CT exams led to over a three-minute reduction in median reporting time, according to newly reported research.
In the first of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed recently published research showing significant declines in computed tomography (CT) radiation dosing over the past decade.
A new study shows that even small plaque volume may be associated with significantly higher risk for cardiovascular events, making the enhanced spatial resolution available with advanced imaging even more critical in risk stratification.
In comparison to contrast-enhanced CT, FAPI PET was associated with over 27 percent higher sensitivity for peritoneal carcinomatosis in the small bowel and 53 percent higher sensitivity in the upper abdomen, according to a new study involving 200 women with primary ovarian carcinoma.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
2
Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?
3
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
4
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
5